CellPly, a Bologna, Italy-based innovative startup which specializes in molecular diagnostics, raised €2M in seed funding.
Backers included Italian Angels for Growth (IAG), Zernike META Ventures, via its Fondo Ingenium Emilia Romagna II, and Atlante Seed (led by IMI Fondi Chiusi – Intesa Sanpaolo Group), team members and several angels.
The company intends to use the funds to complete the prototypying phase of its diagnostics platform.
Founded in 2013 by Prof. Roberto Guerrieri (Bologna University) and led by Massimo Bocchi, President and CEO, Cellply is a biotechnology company committed to the development of solutions for personalized cancer therapy based on diagnostic platforms that define cell response to drug treatments.
Its micro-technologies enable the ex-vivo measurement of the response of each cell in the sample to diverse drug treatments while maintaining tumor microenvironment characteristics. The technology supports the automation of biological protocols and allows the integration of sample preparation and functional analysis procedures.